CDXS
Codexis Inc.
$1.54
-$0.03(-1.91%)
34
Overall
60
Value
9
Tech
--
Quality
Market Cap
$159.87M
Volume
1.24M
52W Range
$1.55 - $6.08
Target Price
$6.75
Company Overview
| Mkt Cap | $159.87M | Price | $1.54 |
| Volume | 1.24M | Change | -1.91% |
| P/E Ratio | -2.4 | Open | $1.58 |
| Revenue | $59.3M | Prev Close | $1.57 |
| Net Income | $-65.3M | 52W Range | $1.55 - $6.08 |
| Div Yield | N/A | Target | $6.75 |
| Overall | 34 | Value | 60 |
| Quality | -- | Technical | 9 |
No chart data available
About Codexis Inc.
Codexis, Inc. provides enzymatic solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, and enhance novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a license agreement with Aldevron LLC and Pfizer Inc. The company was incorporated in 2002 and is headquartered in Redwood City, California.
Sector: Healthcare
Industry: Biotechnology
Latest News
Analysts Have Conflicting Sentiments on These Healthcare Companies: Codexis (CDXS), Milestone Pharmaceuticals (MIST) and Astria Therapeutics (ATXS)
Brian Anderson•10 days ago
Codexis (CDXS) Gets a Buy from Craig-Hallum
TipRanks Auto-Generated Intelligence Newsdesk•19 days ago
Codexis (CDXS) Gets a Buy from Craig-Hallum
TipRanks Auto-Generated Intelligence Newsdesk•a month ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | CDXS | $1.54 | -1.9% | 1.24M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |